<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:04e28feb-0224-48c2-9aed-5419303ac6e2,g:7c5adb88-3a13-4fc9-bea7-995fc46bc2d7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_b2620f39-86f4-47ff-a512-33fc574ddc6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_us-gaap_LongTermLineOfCredit_b2620f39-86f4-47ff-a512-33fc574ddc6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5228d23-5d9f-443a-9a93-993d7fab4a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b5228d23-5d9f-443a-9a93-993d7fab4a20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6f51d411-b87f-415a-b951-af1bafc2c8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_us-gaap_LiabilitiesCurrent_6f51d411-b87f-415a-b951-af1bafc2c8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_16f6f72f-a6d1-4593-8d44-60632c25a03d" xlink:href="cpix-20210331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5c0fe74-8c60-40c5-945c-32c2b0627eb7" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_16f6f72f-a6d1-4593-8d44-60632c25a03d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e568a20c-8bcb-4841-8d52-ff86629ea167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_71acf409-6094-4b9b-a26a-40317d465f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e568a20c-8bcb-4841-8d52-ff86629ea167" xlink:to="loc_us-gaap_CommonStockValue_71acf409-6094-4b9b-a26a-40317d465f53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8d56a2ca-ca05-4687-95e1-2269d8f2327c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_e568a20c-8bcb-4841-8d52-ff86629ea167" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8d56a2ca-ca05-4687-95e1-2269d8f2327c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_90a5397c-448a-4383-baec-5d5e8cf90da9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:to="loc_us-gaap_Liabilities_90a5397c-448a-4383-baec-5d5e8cf90da9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2791682d-6993-4ca2-99ce-682e962e76ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2791682d-6993-4ca2-99ce-682e962e76ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0520c956-f93e-4733-b530-55caf7852d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_072b7720-1b81-4f08-8654-026723d12fc6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0520c956-f93e-4733-b530-55caf7852d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cb9f5434-3690-4560-8b0a-7c4b292e1cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cb9f5434-3690-4560-8b0a-7c4b292e1cb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9a5c86dc-0093-45e7-b783-803d6299e51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:to="loc_us-gaap_AccountsPayableCurrent_9a5c86dc-0093-45e7-b783-803d6299e51f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_33579ee1-dbb1-49d1-9c79-b0c251611e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7af7f7af-f71a-4b6a-b19d-a92d5a887cab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_33579ee1-dbb1-49d1-9c79-b0c251611e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1232ce5-53d0-4a9c-b220-6489e9cf830e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6bfb8b58-d50e-4c81-8198-95d7de9f584c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1232ce5-53d0-4a9c-b220-6489e9cf830e" xlink:to="loc_us-gaap_StockholdersEquity_6bfb8b58-d50e-4c81-8198-95d7de9f584c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_62309ea2-d0c9-46b9-b027-21bf00f7d50c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1232ce5-53d0-4a9c-b220-6489e9cf830e" xlink:to="loc_us-gaap_MinorityInterest_62309ea2-d0c9-46b9-b027-21bf00f7d50c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b48864e2-c074-40ff-b3d1-a13c66c9f758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b48864e2-c074-40ff-b3d1-a13c66c9f758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_38c577b3-8d89-4a02-90d4-f24cd785b7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_38c577b3-8d89-4a02-90d4-f24cd785b7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8b842e3b-4f3b-4af6-95cc-d474f14e63b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_OtherAssetsCurrent_8b842e3b-4f3b-4af6-95cc-d474f14e63b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2bc73c40-da51-4d75-a6b4-4e97a1c63971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_491fab2c-e283-46d0-8340-8e3fb1c03081" xlink:to="loc_us-gaap_InventoryNet_2bc73c40-da51-4d75-a6b4-4e97a1c63971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_da8b5365-c2ae-4b2a-b9ef-c51a9f38179a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_da8b5365-c2ae-4b2a-b9ef-c51a9f38179a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fa47775f-e81c-4def-9e88-ee70b420933c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_Goodwill_fa47775f-e81c-4def-9e88-ee70b420933c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_35ede9dc-f661-4883-9db2-19b42c89ee29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_InventoryNoncurrent_35ede9dc-f661-4883-9db2-19b42c89ee29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_001eb5a8-6758-45fc-989d-1d3de2b48f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_AssetsCurrent_001eb5a8-6758-45fc-989d-1d3de2b48f1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7c6701c4-1271-4c47-b18b-36306feb1f89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7c6701c4-1271-4c47-b18b-36306feb1f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90fd4d35-96a2-49bd-a7f6-0e4ab7ed62ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_90fd4d35-96a2-49bd-a7f6-0e4ab7ed62ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21563db4-3206-4b05-9d40-5dc53e2803e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3370417d-5c4d-4917-b5e4-593e3ba95dd8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21563db4-3206-4b05-9d40-5dc53e2803e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0978bd50-2432-41d1-93b6-a4fa63249fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0978bd50-2432-41d1-93b6-a4fa63249fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_bb371247-d3c6-475c-8b08-ccf97ba4dd89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_SellingAndMarketingExpense_bb371247-d3c6-475c-8b08-ccf97ba4dd89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ab9177-3db9-49b3-8df0-41cca5ed453f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ab9177-3db9-49b3-8df0-41cca5ed453f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9023925a-d44a-4145-ad11-384d4f61a390" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9023925a-d44a-4145-ad11-384d4f61a390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5072e1f9-0c53-45f0-a002-e01b0e3071bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_75803283-7b9c-441b-94b8-7a8062256ffa" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5072e1f9-0c53-45f0-a002-e01b0e3071bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9607b51f-0162-448a-b552-77b0aec6edcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:to="loc_us-gaap_OperatingIncomeLoss_9607b51f-0162-448a-b552-77b0aec6edcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c90077d5-b8de-4416-a0cf-8124d657bb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c90077d5-b8de-4416-a0cf-8124d657bb82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5c4490db-76dd-4009-98a3-e0bc3bfa9415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_60d56433-1384-4db4-8d76-0317c3ca3821" xlink:to="loc_us-gaap_InterestExpense_5c4490db-76dd-4009-98a3-e0bc3bfa9415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_63aae7cd-315c-410e-b4be-8833d68bed66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4ad54bea-a183-43c4-af24-0516da92b952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_63aae7cd-315c-410e-b4be-8833d68bed66" xlink:to="loc_us-gaap_ProfitLoss_4ad54bea-a183-43c4-af24-0516da92b952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a7902cf1-7c9b-4c3b-8183-18d7db3b0649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_63aae7cd-315c-410e-b4be-8833d68bed66" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a7902cf1-7c9b-4c3b-8183-18d7db3b0649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5caa9ac4-db64-41ae-8517-5198af0aaf74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_91bdc017-983f-4ed8-95fb-49a7aae1fbf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5caa9ac4-db64-41ae-8517-5198af0aaf74" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_91bdc017-983f-4ed8-95fb-49a7aae1fbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6d15ab0b-d8f8-4be4-91f4-6952846adaad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_5caa9ac4-db64-41ae-8517-5198af0aaf74" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6d15ab0b-d8f8-4be4-91f4-6952846adaad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a35d4b6-0317-4a6c-bfd1-9f5328c5f06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a281753-480f-41b7-9c84-c3aa33359ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8a35d4b6-0317-4a6c-bfd1-9f5328c5f06d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0a281753-480f-41b7-9c84-c3aa33359ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fae2351e-cafd-48ff-b351-25dee2140c34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8a35d4b6-0317-4a6c-bfd1-9f5328c5f06d" xlink:to="loc_us-gaap_CostsAndExpenses_fae2351e-cafd-48ff-b351-25dee2140c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9bd317bf-53a2-4c9c-a9b5-d8db2a74de0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b2903a23-81d1-416b-81d3-2f46c6f2e355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9bd317bf-53a2-4c9c-a9b5-d8db2a74de0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_b2903a23-81d1-416b-81d3-2f46c6f2e355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72ab65b1-fff1-44a4-bfd5-0008a16b76c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9bd317bf-53a2-4c9c-a9b5-d8db2a74de0e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72ab65b1-fff1-44a4-bfd5-0008a16b76c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4e72b53-5ef2-424d-b906-15a1b00943be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e4c2e808-ee43-49d4-ab51-81683ba9f88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4e72b53-5ef2-424d-b906-15a1b00943be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e4c2e808-ee43-49d4-ab51-81683ba9f88d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2c19fe6d-47ef-4b78-a69c-ec052084eb0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4e72b53-5ef2-424d-b906-15a1b00943be" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2c19fe6d-47ef-4b78-a69c-ec052084eb0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1752836-a40c-47c6-bac4-6ec91be796d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a1752836-a40c-47c6-bac4-6ec91be796d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d51236d9-135c-4d3b-b586-d1882ae20a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d51236d9-135c-4d3b-b586-d1882ae20a3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_41f57645-f1e2-4f4a-81e4-c00c28d9e965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6dd5a862-e85c-4ab5-a72e-0bf1bbbe522f" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_41f57645-f1e2-4f4a-81e4-c00c28d9e965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_c0cdbe4e-ce4f-4681-a6ae-5120c4bcdb76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_c0cdbe4e-ce4f-4681-a6ae-5120c4bcdb76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_caaa0141-fd95-4da0-a20c-c6f79c1a1c85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_caaa0141-fd95-4da0-a20c-c6f79c1a1c85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_bcf768ce-0bef-4cf2-9024-f6f88b0d6d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_bcf768ce-0bef-4cf2-9024-f6f88b0d6d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36e6462b-469d-4121-96a4-69da507b0c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_36e6462b-469d-4121-96a4-69da507b0c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_38b4b9f9-7486-49bd-8215-e0af0bd06c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_01fa248f-15bc-42c6-8ed3-3f6794091880" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_38b4b9f9-7486-49bd-8215-e0af0bd06c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_660088d3-58d5-4603-b473-c726dbc881ec" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_660088d3-58d5-4603-b473-c726dbc881ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_494ff29c-2dd9-42e7-8e87-32105bb10b7c" xlink:href="cpix-20210331.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_494ff29c-2dd9-42e7-8e87-32105bb10b7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8914839a-1c83-4af3-9b83-3c2e8c53d3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8914839a-1c83-4af3-9b83-3c2e8c53d3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cace72e4-4fec-4495-9e04-36f4cee19b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cace72e4-4fec-4495-9e04-36f4cee19b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_81253525-61b8-45a1-bf39-5494aac4a1e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_81253525-61b8-45a1-bf39-5494aac4a1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_70ff0a45-5dd9-423c-a309-e76d8ef0936a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_70ff0a45-5dd9-423c-a309-e76d8ef0936a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c0bb1cbb-039c-4351-8bbc-c370f961eb76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c0bb1cbb-039c-4351-8bbc-c370f961eb76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1f1ed2d1-db55-48bd-a0a8-7ea8614ecfc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1f1ed2d1-db55-48bd-a0a8-7ea8614ecfc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_4eb04311-5b5c-4b3b-b9f1-7fc12cc6cb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_4eb04311-5b5c-4b3b-b9f1-7fc12cc6cb58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1f0331fa-eb6d-4178-8bd2-ceea67a81d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1f0331fa-eb6d-4178-8bd2-ceea67a81d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3c1ab56a-ce9c-4f9c-ae04-e8f2dae0cd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_65a93c04-c088-4635-a826-bd586caec656" xlink:to="loc_us-gaap_ShareBasedCompensation_3c1ab56a-ce9c-4f9c-ae04-e8f2dae0cd58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0bdda33-bbeb-4f6c-9e18-5a03e0970824" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0bdda33-bbeb-4f6c-9e18-5a03e0970824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cd14462-8f67-44ce-a88f-7df44e87884a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cd14462-8f67-44ce-a88f-7df44e87884a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60960018-fcf6-4f00-ad9d-96e61ea5113b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f2b0dab-9a84-43c1-b0b8-e994e7a10f53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60960018-fcf6-4f00-ad9d-96e61ea5113b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20210331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e09ffd23-9ef9-4276-8e83-1cb9b91b49ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95893f01-1a5f-4477-89af-268fe7602219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e09ffd23-9ef9-4276-8e83-1cb9b91b49ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_95893f01-1a5f-4477-89af-268fe7602219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d110141b-e483-47f9-8d7a-00645efb16c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e09ffd23-9ef9-4276-8e83-1cb9b91b49ce" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d110141b-e483-47f9-8d7a-00645efb16c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20210331.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20210331.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_670cc59f-7923-403a-aeca-603672878550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_670cc59f-7923-403a-aeca-603672878550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0a3ac672-7b58-4be4-ae87-40fba5d07dbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0a3ac672-7b58-4be4-ae87-40fba5d07dbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_97194357-4698-4cc0-9867-30e0633ea2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_62303abe-46b0-435c-ba5a-5d3d8fa42be6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_97194357-4698-4cc0-9867-30e0633ea2d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f5540d5a-efa8-4b10-a1be-36153e5a9339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e9662682-b7f0-4d76-aa83-cca9e7760fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5540d5a-efa8-4b10-a1be-36153e5a9339" xlink:to="loc_us-gaap_InventoryNoncurrent_e9662682-b7f0-4d76-aa83-cca9e7760fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_45c60da5-7316-491f-9dd4-f9d55ce487c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5540d5a-efa8-4b10-a1be-36153e5a9339" xlink:to="loc_us-gaap_InventoryGross_45c60da5-7316-491f-9dd4-f9d55ce487c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20210331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e8b2c0e-c095-4719-a419-522224958e33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87bb5f96-7dcf-4281-afbc-36f7bb5291c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e8b2c0e-c095-4719-a419-522224958e33" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_87bb5f96-7dcf-4281-afbc-36f7bb5291c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d562397-c602-48db-b996-81cdd611c1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6e8b2c0e-c095-4719-a419-522224958e33" xlink:to="loc_us-gaap_OperatingLeaseLiability_2d562397-c602-48db-b996-81cdd611c1a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1d84f93d-263f-44da-83e2-ffae61a495a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1d84f93d-263f-44da-83e2-ffae61a495a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_df69cf80-afda-422d-9fce-053eda3f6a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_df69cf80-afda-422d-9fce-053eda3f6a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7c08c883-ff33-4208-b731-2785649a60b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7c08c883-ff33-4208-b731-2785649a60b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_4105423b-bd12-434e-a790-57cc93801f23" xlink:href="cpix-20210331.xsd#cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4f17ef5d-a6f3-4e75-9d42-d0fe1d281dd4" xlink:to="loc_cpix_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_4105423b-bd12-434e-a790-57cc93801f23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#LeasesRentExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesRentExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20210331.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20210331.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRights"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="simple" xlink:href="cpix-20210331.xsd#AdditionsandReturnsofProductRightsDissolutionPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsDissolutionPaymentsDetails" xlink:type="extended"/>
</link:linkbase>
